$OCGN
Ocugen, Inc. Stock $ocgn

$ocgn Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021009457 Filed on May 07, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.190M	$2.280M
YoY Change	83.77%	-22.18%
% of Gross Profit
Research & Development	$2.872M	$1.652M
YoY Change	73.82%	-56.44%
% of Gross Profit
Depreciation & Amortization	$44.00K	$18.00K
YoY Change	144.44%	23.25%
% of Gross Profit
Operating Expenses	$7.057M	$3.929M
YoY Change	79.61%	-18.84%
Operating Profit	-$7.057M	-$3.929M
YoY Change	79.61%	-18.84%
Interest Expense	$20.00K	$15.00K
YoY Change	33.33%	-97.84%
% of Operating Profit
Other Income/Expense, Net	-$20.00K	-$15.00K
YoY Change	33.33%	-98.98%
Pretax Income	-$7.080M	-$3.940M
YoY Change	79.7%	-58.17%
Income Tax
% Of Pretax Income
Net Earnings	-$7.077M	-$3.944M
YoY Change	79.44%	-37.52%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04
Diluted Earnings Per Share	-$0.04	-$74.86K
COMMON SHARES
Basic Shares Outstanding	186.3M shares	52.63M shares
Diluted Shares Outstanding	186.3M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$44.79M	$3.190M
YoY Change	1304.08%	-56.78%
Cash & Equivalents	$44.79M	$3.193M
Short-Term Investments
Other Short-Term Assets	$6.570M	$8.170M
YoY Change	-19.58%	975.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$51.36M	$11.36M
YoY Change	351.98%	39.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$762.0K	$249.0K
YoY Change	206.03%	84.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.578M	$551.2K
YoY Change	186.3%	-91.42%
Total Long-Term Assets	$2.491M	$951.3K
YoY Change	161.86%	-85.8%
TOTAL ASSETS
Total Short-Term Assets	$51.36M	$11.36M
Total Long-Term Assets	$2.491M	$951.3K
Total Assets	$53.85M	$12.31M
YoY Change	337.29%	-17.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.040M	$1.548M
YoY Change	-32.83%	40.76%
Accrued Expenses	$2.870M	$1.384M
YoY Change	107.42%	1297.63%
Deferred Revenue
YoY Change
Short-Term Debt	$374.0K	$0.00
YoY Change
Long-Term Debt Due	$370.0K
YoY Change
Total Short-Term Liabilities	$4.281M	$3.315M
YoY Change	29.14%	43.07%
LONG-TERM LIABILITIES
Long-Term Debt	$1.702M	$1.581M
YoY Change	7.68%
Other Long-Term Liabilities	$1.380M	$3.940K
YoY Change	34925.38%	-99.98%
Total Long-Term Liabilities	$3.077M	$1.702M
YoY Change	80.83%	-90.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.281M	$3.315M
Total Long-Term Liabilities	$3.077M	$1.702M
Total Liabilities	$7.358M	$5.017M
YoY Change	46.67%	-75.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$80.38M	-$55.40M
YoY Change	45.09%	-75.51%
Common Stock	$1.883M	$527.5K
YoY Change	256.99%	-99.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$48.00K	$47.86K
YoY Change	0.28%
Treasury Stock Shares
Shareholders Equity	$46.49M	$7.297M
YoY Change
Total Liabilities & Shareholders Equity	$53.85M	$12.31M
YoY Change	337.29%	-17.01%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$7.077M	-$3.944M
YoY Change	79.44%	-37.52%
Depreciation, Depletion And Amortization	$44.00K	$18.00K
YoY Change	144.44%	23.25%
Cash From Operating Activities	-$5.283M	-$4.686M
YoY Change	12.74%	75.69%
INVESTING ACTIVITIES
Capital Expenditures	$261.0K	$53.00K
YoY Change	392.45%	400.9%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$261.0K	-$53.00K
YoY Change	392.45%	400.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$28.13M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$26.30M	$488.0K
YoY Change	5288.73%	-64.09%
NET CHANGE
Cash From Operating Activities	-$5.283M	-$4.686M
Cash From Investing Activities	-$261.0K	-$53.00K
Cash From Financing Activities	$26.30M	$488.0K
Net Change In Cash	$20.75M	-$4.251M
YoY Change	-588.19%	222.22%
FREE CASH FLOW
Cash From Operating Activities	-$5.283M	-$4.686M
Capital Expenditures	$261.0K	$53.00K
Free Cash Flow	-$5.544M	-$4.739M
YoY Change	16.99%	76.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001372299
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-36751
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	OCUGEN, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3522315
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	263 Great Valley Parkway
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Malvern
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19355
CY2021Q1	dei	City Area Code CityAreaCode	484
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	328-4701
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2021Q1	dei	Trading Symbol TradingSymbol	OCGN
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	198228533	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44792000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24039000	USD
CY2021Q1	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	4988000	USD
CY2020Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	0	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1576000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1839000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	51356000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	25878000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	762000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	633000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1578000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	714000	USD
CY2021Q1	us-gaap	Assets Assets	53847000	USD
CY2020Q4	us-gaap	Assets Assets	27376000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1040000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	395000	USD
CY2021Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2703000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2941000	USD
CY2021Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	374000	USD
CY2020Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	234000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	164000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4281000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3614000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1375000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1702000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1823000	USD
CY2021Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3077000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2212000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	7358000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	5826000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	188277852	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	184133384	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	188156352	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	184011884	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	1883000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1841000	USD
CY2021Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2021Q1	us-gaap	Treasury Stock Value TreasuryStockValue	48000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	48000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	125032000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93059000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80379000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73302000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	46489000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21550000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53847000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27376000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2872000	USD
CY2020Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1652000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4185000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2277000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	7057000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	3929000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7057000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3929000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	20000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	15000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7077000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3944000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	186298122	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52627228	shares
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21550000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	833000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4954000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7077000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	46489000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11019000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	222000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-3944000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	7297000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7077000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	488000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20753000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4251000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-3944000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	44000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	18000	USD
CY2021Q1	ocgn	Non Cash Interest Expense NonCashInterestExpense	20000	USD
CY2020Q1	ocgn	Non Cash Interest Expense NonCashInterestExpense	15000	USD
CY2021Q1	ocgn	Noncash Lease Expense NoncashLeaseExpense	68000	USD
CY2020Q1	ocgn	Noncash Lease Expense NoncashLeaseExpense	48000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	833000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	222000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-493000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-228000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	405000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1225000	USD
CY2021Q1	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-69000	USD
CY2020Q1	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-48000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5283000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24190000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7595000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44943000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3344000	USD
CY2021Q1	us-gaap	Stock Issued1 StockIssued1	4988000	USD
CY2020Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2021Q1	ocgn	Noncash Or Part Noncash Amount Of Deferred Transaction Cost NoncashOrPartNoncashAmountOfDeferredTransactionCost	108000	USD
CY2020Q1	ocgn	Noncash Or Part Noncash Amount Of Deferred Transaction Cost NoncashOrPartNoncashAmountOfDeferredTransactionCost	0	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	44000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021Q1	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	926000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4686000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	261000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-261000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	6000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	6000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28125000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1822000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2020Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	500000	USD
CY2021Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2020Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	6000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26297000	USD
CY2020Q1	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	0	USD
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen, Inc., together with its wholly owned subsidiaries (“Ocugen” or the “Company”), is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The Company is located in Malvern, Pennsylvania, and manages its business as one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Vaccine</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a Co-Development, Supply and Commercialization Agreement (the "Covaxin Agreement") with Bharat Biotech International Limited ("Bharat Biotech"), pursuant to which the Company obtained an exclusive right and license under certain of Bharat Biotech's intellectual property rights, with the right to grant sublicenses to develop, manufacture, and commercialize COVAXIN for the prevention of COVID-19 in humans in the United States, its territories and possessions (the “Ocugen Covaxin Territory”). COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus, an antigen, and an adjuvant. COVAXIN requires a two-dose vaccination regimen given 28 days apart and is stored in standard vaccine storage conditions (2-8°C). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVAXIN has been granted approval for emergency use in India and millions have been dosed to date. The Phase 1 and Phase 2 clinical trials conducted in India reported strong Immunoglobulin G ("IgG") responses against the spike protein, receptor-binding domain ("RBD"), and the nucleocapsid protein of the SARS-CoV-2 virus, along with strong cellular responses. Strong cellular responses are necessary for memory and long-term durability of vaccines. Both the Phase 1 and Phase 2 clinical trials were published in the Lancet. Bharat Biotech is currently conducting a Phase 3 clinical trial in India. Enrollment in the Phase 3 clinical trial is complete. In April 2021, COVAXIN demonstrated positive results in the second interim analysis of the Phase 3 clinical trial showing a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 78%, efficacy against severe COVID-19 disease alone of 100%, and efficacy against asymptomatic COVID-19 infection of 70%. The 78% efficacy result represents a point estimate of vaccine efficacy with a 95% confidence interval of 61% to 88% against mild, moderate, and severe COVID-19 disease. In an in vitro study conducted by the Indian Council of Medical Research ("ICMR")-National Institute of Virology, COVAXIN demonstrated potential effectiveness against the Brazilian variant of SARS-CoV-2, B.1.1.28.2, which contains the E484K mutation found in New York. An additional in vitro study conducted by the ICMR-National Institute of Virology suggested that COVAXIN was effective against the U.K. variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617. These studies suggest that COVAXIN vaccination may be effective against infection from multiple SARS-CoV-2 variants.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently evaluating the clinical and regulatory path for COVAXIN in the United States including obtaining Emergency Use Authorization ("EUA") from the U.S. Food and Drug Administration (the "FDA") and, eventually, biologic license application (“BLA”) approval in the United States, as well as the Company's commercialization strategy, if authorized or approved. The Company has initiated discussions with the FDA regarding the development of COVAXIN and EUA. Consistent with the FDA guidance document on EUA for vaccines to prevent COVID-19, the company has submitted key information and data to date (including preclinical studies, chemistry, manufacturing, and controls ("CMC"), and clinical studies) as a “Master File” for FDA review and input prior to a planned EUA submission. The Company is currently waiting for additional data from Bharat Biotech from the ongoing Phase 3 clinical trial for an EUA submission. See Note 3 for additional information about the terms, rights, and obligations under the Covaxin Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modifier Gene Therapy Platform</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is developing a breakthrough modifier gene therapy platform to generate therapies designed to fulfill unmet medical needs in the area of retinal diseases, including inherited retinal diseases ("IRDs") and dry age-related macular degeneration ("AMD"). The Company's modifier gene therapy platform is based on nuclear hormone receptors (“NHRs”), which have the potential to restore homeostasis, the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, the Company believes that its gene therapy platform, through its use of NHRs, represents a novel approach in that it may address multiple retinal diseases with one product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that OCU400, its first product candidate being developed with its modifier gene therapy platform, has the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse IRDs, including retinitis pigmentosa ("RP") and leber congenital amaurosis ("LCA"). OCU400 has received four Orphan Drug </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designations ("ODDs") from the FDA for the treatment of certain disease genotypes: nuclear receptor subfamily 2 group E member 3 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), centrosomal protein 290 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEP290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), rhodopsin ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), and phosphodiesterase 6B ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PDE6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ß") mutation-associated inherited retinal degenerations. The Company is planning to initiate two Phase 1/2a clinical trials for OCU400 in the United States in the second half of 2021. OCU400 additionally received Orphan Medicinal Product Designation ("OMPD") from the European Commission ("EC"), based on the recommendation of the European Medicines Agency ("EMA"), for RP and LCA in February 2021, which the Company believes further supports the potential broad spectrum application of OCU400 to treat many IRDs. The Company is currently evaluating options to commence OCU400 clinical trials in Europe in 2022. The Company's second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RORA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">") for the treatment of dry AMD. This candidate is currently in preclinical development. The Company is planning to initiate a Phase 1/2a clinical trial for OCU410 in 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel Biologic Therapy for Retinal Diseases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also conducting preclinical development for its biologic product candidate, OCU200. OCU200 is a novel fusion protein designed to treat diabetic macular edema ("DME"), diabetic retinopathy ("DR"), and wet AMD. The Company had a pre-Investigational New Drug ("IND") meeting with the FDA in November 2020 and received guidance on IND-enabling preclinical studies to support the Phase 1/2a study. The Company expects to initiate IND-enabling preclinical studies for OCU200 in 2021 and plans to initiate a Phase 1/2a clinical trial for OCU200 in 2022.</span></div>
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q1	ocgn	Number Of Vaccination Dose Regimen NumberOfVaccinationDoseRegimen	2	dose
CY2021Q1	ocgn	Vaccination Dose Regimen Duration Apart VaccinationDoseRegimenDurationApart	P28D
CY2021Q1	ocgn	Modifier Gene Therapy Platform Number Of Genetic Mutations Target ModifierGeneTherapyPlatformNumberOfGeneticMutationsTarget	1	geneticMutation
CY2021Q1	ocgn	Modifier Gene Therapy Platform Number Of Products ModifierGeneTherapyPlatformNumberOfProducts	1	product
CY2021Q1	ocgn	Number Of Orphan Drug Designations NumberOfOrphanDrugDesignations	4	orphan_drug_designation
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the condensed consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions primarily include those used in the accounting for research and development accruals and the fair value measurement of equity instruments.</span></div>
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44792000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3193000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44943000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3344000	USD
CY2021Q1	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P5Y
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	988000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	859000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	226000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	226000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	762000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	633000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y
CY2021Q1	ocgn	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	1	renewalOption
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	68000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	48000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	30000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	21000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	98000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	69000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1528000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	434000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	164000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1375000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1539000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	433000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y8M12D
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.046
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	163000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	252000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	261000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	269000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	277000	USD
CY2021Q1	ocgn	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	578000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1800000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	261000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1539000	USD
CY2021Q1	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	454000	USD
CY2020Q4	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	512000	USD
CY2021Q1	ocgn	Accrued Liabilities Clinical AccruedLiabilitiesClinical	115000	USD
CY2020Q4	ocgn	Accrued Liabilities Clinical AccruedLiabilitiesClinical	117000	USD
CY2021Q1	ocgn	Accrued Liabilities Professional Fees AccruedLiabilitiesProfessionalFees	1259000	USD
CY2020Q4	ocgn	Accrued Liabilities Professional Fees AccruedLiabilitiesProfessionalFees	405000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	336000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	963000	USD
CY2021Q1	ocgn	Accrued Severance Related Liabilities Current AccruedSeveranceRelatedLiabilitiesCurrent	405000	USD
CY2020Q4	ocgn	Accrued Severance Related Liabilities Current AccruedSeveranceRelatedLiabilitiesCurrent	712000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	134000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	232000	USD
CY2021Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2703000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2941000	USD
CY2021Q1	us-gaap	Severance Costs1 SeveranceCosts1	300000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	2076000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	2057000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	833000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	222000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	9300000	USD
CY2021Q1	ocgn	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	2	segment
CY2020Q4	ocgn	Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Shares To Be Issue Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage	0.04
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.73
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.42
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	300000	USD
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	100000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7077000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-3944000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	186298122	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52627228	shares
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10658317	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12143831	shares

Files In Submission

Name	View Source	Status
0001628280-21-009457-index-headers.html	Edgar Link	pending
0001628280-21-009457-index.html	Edgar Link	pending
0001628280-21-009457.txt	Edgar Link	pending
0001628280-21-009457-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ocgn-20210331.htm	Edgar Link	pending
ocgn-20210331.xsd	Edgar Link	pending
ocgn-20210331x10qxex101.htm	Edgar Link	pending
ocgn-20210331x10qxex102.htm	Edgar Link	pending
ocgn-20210331x10qxex31.htm	Edgar Link	pending
ocgn-20210331x10qxex311.htm	Edgar Link	pending
ocgn-20210331x10qxex312.htm	Edgar Link	pending
ocgn-20210331x10qxex321.htm	Edgar Link	pending
ocgn-20210331_cal.xml	Edgar Link	unprocessable
ocgn-20210331_def.xml	Edgar Link	unprocessable
ocgn-20210331_htm.xml	Edgar Link	completed
ocgn-20210331_lab.xml	Edgar Link	unprocessable
ocgn-20210331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OCGN
Ocugen, Inc. Stock $ocgn

2021 Q1 Form 10-Q Financial Statement

#000162828021009457 Filed on May 07, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN Ocugen, Inc. Stock $ocgn

2021 Q1 Form 10-Q Financial Statement

#000162828021009457 Filed on May 07, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN
Ocugen, Inc. Stock $ocgn